Childhood acute myeloid leukaemia

British Journal of Haematology

Volumn 159, Issue 3, 2012, Pages 259-276

  Rubnitz, Jeffrey E ^a,b   Inaba, Hiroto ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acute myeloid leukaemia; AML; Childhood leukaemia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ARSENIC TRIOXIDE; AZACITIDINE; CASPOFUNGIN; CEFEPIME; CIPROFLOXACIN; CLADRIBINE; CLOFARABINE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 2; LESTAURTINIB; MICAFUNGIN; MITOXANTRONE; MYLOTRAG; PLERIXAFOR; POSACONAZOLE; RETINOIC ACID; SORAFENIB; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ASPERGILLOSIS; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CANDIDIASIS; CARDIOTOXICITY; CAREGIVER SUPPORT; CEBPA GENE; CHILDHOOD CANCER; CHILDHOOD DISEASE; CHILDHOOD LEUKEMIA; DISEASE ASSOCIATION; DNMT3A GENE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FLT3 GENE; GENETIC ASSOCIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IDH1 GENE; IDH2 GENE; LEUKOCYTOSIS; LOW DRUG DOSE; MOLECULAR PATHOLOGY; MUTATOR GENE; NPM1 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; WILM TUMOR 1 GENE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; YOUNG ADULT;

EID: 84867440163     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12040     Document Type: Review

References (174)

1. Abrahamsson, J., Clausen, N., Gustafsson, G., Hovi, L., Jonmundsson, G., Zeller, B., Forestier, E., Heldrup, J. & Hasle, H. (2007) Improved outcome after relapse in children with acute myeloid leukaemia. British Journal of Haematology, 136, 229-236.
2. Abrahamsson, J., Forestier, E., Heldrup, J., Jahnukainen, K., Jonsson, O.G., Lausen, B., Palle, J., Zeller, B. & Hasle, H. (2011) Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. Journal of Clinical Oncology, 29, 310-315.
3. Aladjidi, N., Auvrignon, A., Leblanc, T., Perel, Y., Benard, A., Bordigoni, P., Gandemer, V., Thuret, I., Dalle, J.H., Piguet, C., Pautard, B., Baruchel, A. & Leverger, G. (2003) Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. Journal of Clinical Oncology, 21, 4377-4385.
4. Alexander, S., Nieder, M., Zerr, D.M., Fisher, B.T., Dvorak, C.C. & Sung, L. (2012) Prevention of bacterial infection in pediatric oncology: what do we know, what can we learn? Pediatric Blood and Cancer, 59, 16-20.
5. Andersson, A.K., Miller, D.W., Lynch, J.A., Lemoff, A.S., Cai, Z., Pounds, S.B., Radtke, I., Yan, B., Schuetz, J.D., Rubnitz, J.E., Ribeiro, R.C., Raimondi, S.C., Zhang, J., Mullighan, C.G., Shurtleff, S.A., Schulman, B.A. & Downing, J.R. (2011) IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia, 25, 1570-1577.
6. Arceci, R.J., Sande, J., Lange, B., Shannon, K., Franklin, J., Hutchinson, R., Vik, T.A., Flowers, D., Aplenc, R., Berger, M.S., Sherman, M.L., Smith, F.O., Bernstein, I. & Sievers, E.L. (2005) Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood, 106, 1183-1188.
7. Bachas, C., Schuurhuis, G.J., Hollink, I.H.I.M., Kwidama, Z.J., Goemans, B.F., Zwaan, C.M., van den Heuvel-Eibrink, M.M., de Bont, E.S.J.M., Reinhardt, D., Creutzig, U., de Haas, V., Assaraf, Y.G., Kaspers, G.J.L. & Cloos, J. (2010) High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood, 116, 2752-2758.
8. Balgobind, B.V., Raimondi, S.C., Harbott, J., Zimmermann, M., Alonzo, T.A., Auvrignon, A., Beverloo, H.B., Chang, M., Creutzig, U., Dworzak, M.N., Forestier, E., Gibson, B., Hasle, H., Harrison, C.J., Heerema, N.A., Kaspers, G.J., Leszl, A., Litvinko, N., Nigro, L.L., Morimoto, A., Perot, C., Pieters, R., Reinhardt, D., Rubnitz, J.E., Smith, F.O., Stary, J., Stasevich, I., Strehl, S., Taga, T., Tomizawa, D., Webb, D., Zemanova, Z., Zwaan, C.M. & van den Heuvel-Eibrink, M.M. (2009) Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood, 114, 2489-2496.
9. Balgobind, B.V., Zwaan, C.M., Pieters, R. & van den Heuvel-Eibrink, M.M. (2011) The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia, 25, 1239-1248.
10. Bally, C., Fadlallah, J., Leverger, G., Bertrand, Y., Robert, A., Baruchel, A., Guerci, A., Recher, C., Raffoux, E., Thomas, X., Leblanc, T., Idres, N., Cassinat, B., Vey, N., Chomienne, C., Dombret, H., Sanz, M., Fenaux, P. & Ades, L. (2012) Outcome of Acute Promyelocytic Leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group. Journal of Clinical Oncology, 30, 1641-1646.
11. Brethon, B., Yakouben, K., Oudot, C., Boutard, P., Bruno, B., Jérome, C., Nelken, B., De Lumley, L., Bertrand, Y., Dalle, J.-H., Chevret, S., Leblanc, T. & Baruchel, A. (2008) Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. British Journal of Haematology, 143, 541-547.
12. Brisco, J., Hughes, E., Neoh, S.H., Sykes, P.J., Bradstock, K., Enno, A., Szer, J., McCaul, K. & Morley, A.A. (1996) Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood, 87, 5251-5256.
13. Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G. & Pazdur, R. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical Cancer Research, 7, 1490-1496.
14. Brown, P., McIntyre, E., Rau, R., Meshinchi, S., Lacayo, N., Dahl, G., Alonzo, T.A., Chang, M., Arceci, R.J. & Small, D. (2007) The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood, 110, 979-985.
15. Buccisano, F., Maurillo, L., Del Principe, M.I., Del, P.G., Sconocchia, G., Lo-Coco, F., Arcese, W., Amadori, S. & Venditti, A. (2012) Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood, 119, 332-341.
16. Bunin, N.J., Davies, S.M., Aplenc, R., Camitta, B.M., DeSantes, K.B., Goyal, R.K., Kapoor, N., Kernan, N.A., Rosenthal, J., Smith, F.O. & Eapen, M. (2008) Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. Journal of Clinical Oncology, 26, 4326-4332.
17. Burger, J.A. & Peled, A. (2009) CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia, 23, 43-52.
18. Burnett, A.K., Wheatley, K., Goldstone, A.H., Stevens, R.F., Hann, I.M., Rees, J.H. & Harrison, G. (2002) The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology, 118, 385-400.
19. Burnett, A.K., Hills, R.K., Milligan, D.W., Goldstone, A.H., Prentice, A.G., McMullin, M.F., Duncombe, A., Gibson, B. & Wheatley, K. (2010) Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Journal of Clinical Oncology, 28, 586-595.
20. Burnett, A.K., Hills, R.K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N.H., Yin, J.A., Hunter, A., Goldstone, A.H. & Wheatley, K. (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. Journal of Clinical Oncology, 29, 369-377.
21. Campana, D. (2008) Status of minimal residual disease testing in childhood haematological malignancies. British Journal of Haematology, 143, 481-489.
22. Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., de Revel, T., Gastaud, L., de Gunzburg, N., Contentin, N., Henry, E., Marolleau, J.-P., Aljijakli, A., Rousselot, P., Fenaux, P., Preudhomme, C., Chevret, S. & Dombret, H. (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet, 379, 1508-1516.
23. Cooper, T.M., Franklin, J., Gerbing, R.B., Alonzo, T.A., Hurwitz, C., Raimondi, S.C., Hirsch, B., Smith, F.O., Mathew, P., Arceci, R.J., Feusner, J., Iannone, R., Lavey, R.S., Meshinchi, S. & Gamis, A. (2012) AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer, 118, 761-769.
24. Coustan-Smith, E., Ribeiro, R.C., Rubnitz, J.E., Razzouk, B.I., Pui, C.H., Pounds, S., Andreansky, M., Behm, F.G., Raimondi, S.C., Shurtleff, S.A., Downing, J.R. & Campana, D. (2003) Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. British Journal of Haematology, 123, 243-252.
25. Creutzig, U., Ritter, J., Zimmermann, M., Hermann, J., Gardner, H., Sawatzki, D.B., Niemeyer, C.M., Schwabe, D., Selle, B., Boos, J., Kuhl, J. & Feldges, A. (2001a) Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia, 15, 348-354.
26. Creutzig, U., Ritter, J., Zimmermann, M., Reinhardt, D., Hermann, J., Berthold, F., Henze, G., Jurgens, H., Kabisch, H., Havers, W., Reiter, A., Kluba, U., Niggli, F. & Gadner, H. (2001b) Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt- Munster 93. Journal of Clinical Oncology, 19, 2705-2713.
27. Creutzig, U., Zimmermann, M., Lehrnbecher, T., Graf, N., Hermann, J., Niemeyer, C.M., Reiter, A., Ritter, J., Dworzak, M., Stary, J. & Reinhardt, D. (2006) Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. Journal of Clinical Oncology, 24, 4499-4506.
28. Creutzig, U., Zimmerman, M., Dworzak, M., Bourquin, J.P., Neuhoff, C., Sander, A., Stary, J. & Reinhardt, D. (2010) Study AML-BFM 2004: improved survival in childhood acute myeloid leukemia without increased toxicity. ASH Annual Meeting Abstracts, 116, 181.
29. Crews, K.R., Gandhi, V., Srivastava, D.K., Razzouk, B.I., Tong, X., Behm, F.G., Plunkett, W., Raimondi, S.C., Pui, C.H., Rubnitz, J.E., Stewart, C.F. & Ribeiro, R.C. (2002) Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. Journal of Clinical Oncology, 20, 4217-4224.
30. Damm, F., Thol, F., Hollink, I., Zimmermann, M., Reinhardt, K., van den Heuvel-Eibrink, M.M., Zwaan, C.M., de Haas, V., Creutzig, U., Klusmann, J.-H., Krauter, J., Heuser, M., Ganser, A., Reinhardt, D. & Thiede, C. (2011) Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia, 25, 1704-1710.
31. Dezern, A.E., Sung, A., Kim, S., Smith, B.D., Karp, J.E., Gore, S.D., Jones, R.J., Fuchs, E., Luznik, L., McDevitt, M. & Levis, M. (2011) Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biology of Blood and Marrow Transplantation, 17, 1404-1409.
32. Ding, L., Ley, T.J., Larson, D.E., Miller, C.A., Koboldt, D.C., Welch, J.S., Ritchey, J.K., Young, M.A., Lamprecht, T., McLellan, M.D., McMichael, J.F., Wallis, J.W., Lu, C., Shen, D., Harris, C.C., Dooling, D.J., Fulton, R.S., Fulton, L.L., Chen, K., Schmidt, H., Kalicki-Veizer, J., Magrini, V.J., Cook, L., McGrath, S.D., Vickery, T.L., Wendl, M.C., Heath, S., Watson, M.A., Link, D.C., Tomasson, M.H., Shannon, W.D., Payton, J.E., Kulkarni, S., Westervelt, P., Walter, M.J., Graubert, T.A., Mardis, E.R., Wilson, R.K. & DiPersio, J.F. (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 481, 506-510.
33. Duval, M., Klein, J.P., He, W., Cahn, J.-Y., Cairo, M., Camitta, B.M., Kamble, R., Copelan, E., de Lima, M., Gupta, V., Keating, A., Lazarus, H.M., Litzow, M.R., Marks, D.I., Maziarz, R.T., Rizzieri, D.A., Schiller, G., Schultz, K.R., Tallman, M.S. & Weisdorf, D. (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. Journal of Clinical Oncology, 28, 3730-3738.
34. Dvorak, C.C., Fisher, B.T., Sung, L., Steinbach, W.J., Nieder, M., Alexander, S. & Zaoutis, T.E. (2012) Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data. Pediatric Blood and Cancer, 59, 21-26.
35. Eapen, M., Rubinstein, P., Zhang, M.J., Stevens, C., Kurtzberg, J., Scaradavou, A., Loberiza, F.R., Champlin, R.E., Klein, J.P., Horowitz, M.M. & Wagner, J.E. (2007) Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet, 369, 1947-1954.
36. Eppert, K., Takenaka, K., Lechman, E.R., Waldron, L., Nilsson, B., van Galen, P., Metzeler, K.H., Poepp, A., Ling, V., Beyene, J., Canty, A.J., Danska, J.S., Bohlander, S.K., Buske, C., Minden, M.D., Golub, T.R., Jurisica, I., Ebert, B.L. & Dick, J.E. (2011) Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Medicine, 17, 1086-1093.
37. Estey, E., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L.E., Koller, C. & Kornblau, S. (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. Journal of Clinical Oncology, 12, 671-678.
38. Faderl, S., Gandhi, V., O'Brien, S., Bonate, P., Cortes, J., Estey, E., Beran, M., Wierda, W., Garcia-Manero, G., Ferrajoli, A., Estrov, Z., Giles, F.J., Du, M., Kwari, M., Keating, M., Plunkett, W. & Kantarjian, H. (2005) Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood, 105, 940-947.
39. Fernandez, H.F., Sun, Z., Yao, X., Litzow, M.R., Luger, S.M., Paietta, E.M., Racevskis, J., Dewald, G.W., Ketterling, R.P., Bennett, J.M., Rowe, J.M., Lazarus, H.M. & Tallman, M.S. (2009) Anthracycline dose intensification in acute myeloid leukemia. New England Journal of Medicine, 361, 1249-1259.
40. Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W.H. & Campana, D. (2009) Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Research, 69, 4010-4017.
41. Gale, R.E., Hills, R., Pizzey, A.R., Kottaridis, P.D., Swirsky, D., Gilkes, A.F., Nugent, E., Mills, K.I., Wheatley, K., Solomon, E., Burnett, A.K., Linch, D.C. & Grimwade, D. (2005) Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood, 106, 3768-3776.
42. Gamis, A.S. (2005) Acute myeloid leukemia and down syndrome evolution of modern therapy-state of the art review. Pediatric Blood and Cancer, 44, 13-20.
43. Gandhi, V., Estey, E., Keating, M.J. & Plunkett, W. (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. Journal of Clinical Oncology, 11, 116-124.
44. Garcia-Manero, G., Kantarjian, H.M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W.G., Ravandi, F., Koller, C., Xiao, L., Faderl, S., Estrov, Z., Cortes, J., O'Brien, S., Estey, E., Bueso-Ramos, C., Fiorentino, J., Jabbour, E. & Issa, J.P. (2006) Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood, 108, 3271-3279.
45. Garcia-Manero, G., Tambaro, F.P., Bekele, N.B., Yang, H., Ravandi, F., Jabbour, E., Borthakur, G., Kadia, T.M., Konopleva, M.Y., Faderl, S., Cortes, J.E., Brandt, M., Hu, Y., McCue, D., Newsome, W.M., Pierce, S.R., de Lima, M. & Kantarjian, H.M. (2012) Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Journal of Clinical Oncology, 30, 2204-2210.
46. Ge, Y., Stout, M.L., Tatman, D.A., Jensen, T.L., Buck, S., Thomas, R.L., Ravindranath, Y., Matherly, L.H. & Taub, J.W. (2005) GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. Journal of the National Cancer Institute, 97, 226-231.
47. Ge, Y., Dombkowski, A.A., Lafiura, K.M., Tatman, D., Yedidi, R.S., Stout, M.L., Buck, S.A., Massey, G., Becton, D.L., Weinstein, H.J., Ravindranath, Y., Matherly, L.H. & Taub, J.W. (2006) Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood, 107, 1570-1581.
48. Gerber, J.M., Smith, B.D., Ngwang, B., Zhang, H., Vala, M.S., Morsberger, L., Galkin, S., Collector, M.I., Perkins, B., Levis, M.J., Griffin, C.A., Sharkis, S.J., Borowitz, M.J., Karp, J.E. & Jones, R.J. (2012) A clinically relevant population of leukemic CD34+. Blood, 119, 3571-3577.
49. Ghavamzadeh, A., Alimoghaddam, K., Rostami, S., Ghaffari, S.H., Jahani, M., Iravani, M., Mousavi, S.A., Bahar, B. & Jalili, M. (2011) Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. Journal of Clinical Oncology, 29, 2753-2757.
50. Gibson, B.E., Webb, D.K., Howman, A.J., de Graaf, S.S., Harrison, C.J. & Wheatley, K. (2011) Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. British Journal of Haematology, 155, 366-376.
51. Giebel, S., Locatelli, F., Lamparelli, T., Velardi, A., Davies, S., Frumento, G., Maccario, R., Bonetti, F., Wojnar, J., Martinetti, M., Frassoni, F., Giorgiani, G., Bacigalupo, A. & Holowiecki, J. (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood, 102, 814-819.
52. Goardon, N., Marchi, E., Atzberger, A., Quek, L., Schuh, A., Soneji, S., Woll, P., Mead, A., Alford, K.A., Rout, R., Chaudhury, S., Gilkes, A., Knapper, S., Beldjord, K., Begum, S., Rose, S., Geddes, N., Griffiths, M., Standen, G., Sternberg, A., Cavenagh, J., Hunter, H., Bowen, D., Killick, S., Robinson, L., Price, A., Macintyre, E., Virgo, P., Burnett, A., Craddock, C., Enver, T., Jacobsen, S.E., Porcher, C. & Vyas, P. (2011) Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell, 19, 138-152.
53. Godley, L.A. & Le Beau, M.M. (2012) The histone code and treatments for acute myeloid leukemia. New England Journal of Medicine, 366, 960-961.
54. Gooley, T.A., Chien, J.W., Pergam, S.A., Hingorani, S., Sorror, M.L., Boeckh, M., Martin, P.J., Sandmaier, B.M., Marr, K.A., Appelbaum, F.R., Storb, R. & McDonald, G.B. (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. New England Journal of Medicine, 363, 2091-2101.
55. Gorman, M.F., Ji, L., Ko, R.H., Barnette, P., Bostrom, B., Hutchinson, R., Raetz, E., Seibel, N.L., Twist, C.J., Eckroth, E., Sposto, R., Gaynon, P.S. & Loh, M.L. (2010) Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatric Blood and Cancer, 55, 421-429.
56. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 92, 2322-2333.
57. Guzman, M.L., Rossi, R.M., Neelakantan, S., Li, X., Corbett, C.A., Hassane, D.C., Becker, M.W., Bennett, J.M., Sullivan, E., Lachowicz, J.L., Vaughan, A., Sweeney, C.J., Matthews, W., Carroll, M., Liesveld, J.L., Crooks, P.A. & Jordan, C.T. (2007a) An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood, 110, 4427-4435.
58. Guzman, M.L., Li, X., Corbett, C.A., Rossi, R.M., Bushnell, T., Liesveld, J.L., Hebert, J., Young, F. & Jordan, C.T. (2007b) Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1, 2, 4-thiadiazolidine, 3, 5 dione (TDZD-8). Blood, 110, 4436-4444.
59. Haferlach, T., Kohlmann, A., Klein, H.U., Ruckert, C., Dugas, M., Williams, P.M., Kern, W., Schnittger, S., Bacher, U., Loffler, H. & Haferlach, C. (2009) AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia, 23, 934-943.
60. Hann, I.M., Stevens, R.F., Goldstone, A.H., Rees, J.K., Wheatley, K., Gray, R.G. & Burnett, A.K. (1997) Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood, 89, 2311-2318.
61. Harris, W.J., Huang, X., Lynch, J.T., Spencer, G.J., Hitchin, J.R., Li, Y., Ciceri, F., Blaser, J.G., Greystoke, B.F., Jordan, A.M., Miller, C.J., Ogilvie, D.J. & Somervaille, T.C. (2012) The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell, 21, 473-487.
62. Harrison, C., Hills, R., Moorman, A.V., Grimwade, D., Hann, I., Webb, D., Wheatley, K., de Graaf, S.S., van den Berg, E., Burnett, A. & Gibson, B. (2010) Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12. Journal of Clinical Oncology, 28, 2674-2681.
63. Hasle, H., Alonzo, T.A., Auvrignon, A., Behar, C., Chang, M., Creutzig, U., Fischer, A., Forestier, E., Fynn, A., Haas, O.A., Harbott, J., Harrison, C.J., Heerema, N.A., van den Heuvel-Eibrink, M.M., Kaspers, G.J., Locatelli, F., Noellke, P., Polychronopoulou, S., Ravindranath, Y., Razzouk, B., Reinhardt, D., Savva, N.N., Stark, B., Suciu, S., Tsukimoto, I., Webb, D.K., Wojcik, D., Woods, W.G., Zimmermann, M., Niemeyer, C.M. & Raimondi, S.C. (2007) Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood, 109, 4641-4647.
64. Hasle, H., Abrahamsson, J., Forestier, E., Ha, S.Y., Heldrup, J., Jahnukainen, K., Jonsson, O.G., Lausen, B., Palle, J. & Zeller, B. (2012) Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood, 120, 978-984.
65. Hijiya, N., Gaynon, P., Barry, E., Silverman, l., Thomson, B., Chu, R., Cooper, T., Kadota, R., Rytting, M., Steinherz, P., Shen, V., Jeha, S., Abichandani, R. & Carroll, W.L. (2009) A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia, 23, 2259-2264.
66. Ho, P.A., Alonzo, T.A., Gerbing, R.B., Pollard, J., Stirewalt, D.L., Hurwitz, C., Heerema, N.A., Hirsch, B., Raimondi, S.C., Lange, B., Franklin, J.L., Radich, J.P. & Meshinchi, S. (2009) Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood, 113, 6558-6566.
67. Ho, P.A., Zeng, R., Alonzo, T.A., Gerbing, R.B., Miller, K.L., Pollard, J.A., Stirewalt, D.L., Heerema, N.A., Raimondi, S.C., Hirsch, B., Franklin, J.L., Lange, B. & Meshinchi, S. (2010) Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood, 116, 702-710.
68. Ho, P.A., Kuhn, J., Gerbing, R.B., Pollard, J.A., Zeng, R., Miller, K.L., Heerema, N.A., Raimondi, S.C., Hirsch, B.A., Franklin, J.L., Lange, B., Gamis, A.S., Alonzo, T.A. & Meshinchi, S. (2011a) WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. Journal of Clinical Oncology, 29, 704-711.
69. Ho, P.A., Kopecky, K.J., Alonzo, T.A., Gerbing, R.B., Miller, K.L., Kuhn, J., Zeng, R., Ries, R.E., Raimondi, S.C., Hirsch, B.A., Oehler, V., Hurwitz, C.A., Franklin, J.L., Gamis, A.S., Petersdorf, S.H., Anderson, J.E., Godwin, J.E., Reaman, G.H., Willman, C.L., Bernstein, I.D., Radich, J.P., Appelbaum, F.R., Stirewalt, D.L. & Meshinchi, S. (2011b) Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. Blood, 118, 4561-4566.
70. Hollink, I.H., Zwaan, C.M., Zimmermann, M., Arentsen-Peters, T.C., Pieters, R., Cloos, J., Kaspers, G.J., de Graaf, S.S., Harbott, J., Creutzig, U., Reinhardt, D., van den Heuvel-Eibrink, M.M. & Thiede, C. (2009a) Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia, 23, 262-270.
71. Hollink, I.H., van den Heuvel-Eibrink, M.M., Zimmermann, M., Balgobind, B.V., Arentsen-Peters, S.T., Alders, M., Willasch, A., Kaspers, G.J., Trka, J., Baruchel, A., de Graaf, S.S., Creutzig, U., Pieters, R., Reinhardt, D. & Zwaan, C.M. (2009b) Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood, 113, 5951-5960.
72. Hollink, I.H., van den Heuvel-Eibrink, M.M., Arentsen-Peters, S.T., Pratcorona, M., Abbas, S., Kuipers, J.E., van Galen, J.F., Beverloo, H.B., Sonneveld, E., Kaspers, G.J., Trka, J., Baruchel, A., Zimmermann, M., Creutzig, U., Reinhardt, D., Pieters, R., Valk, P.J. & Zwaan, C.M. (2011) NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood, 118, 3645-3656.
73. Horan, J.T., Alonzo, T.A., Lyman, G.H., Gerbing, R.B., Lange, B.J., Ravindranath, Y., Becton, D., Smith, F.O. & Woods, W.G. (2008) Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. Journal of Clinical Oncology, 26, 5797-5801.
74. Horan, J.T., Logan, B.R., Agovi-Johnson, M.A., Lazarus, H.M., Bacigalupo, A.A., Ballen, K.K., Bredeson, C.N., Carabasi, M.H., Gupta, V., Hale, G.A., Khoury, H.J., Juckett, M.B., Litzow, M.R., Martino, R., McCarthy, P.L., Smith, F.O., Rizzo, J.D. & Pasquini, M.C. (2011) Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? Journal of Clinical Oncology, 29, 805-813.
75. Imai, C., Iwamoto, S. & Campana, D. (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood, 106, 376-383.
76. Inaba, H., Fan, Y., Pounds, S., Geiger, T.L., Rubnitz, J.E., Ribeiro, R.C., Pui, C.H. & Razzouk, B.I. (2008) Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer, 113, 522-529.
77. Inaba, H., Rubnitz, J.E., Coustan-Smith, E., Li, L., Furmanski, B.D., Mascara, G.P., Heym, K.M., Christensen, R., Onciu, M., Shurtleff, S.A., Pounds, S.B., Pui, C.H., Ribeiro, R.C., Campana, D. & Baker, S.D. (2011) Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. Journal of Clinical Oncology, 29, 3293-3300.
78. Inaba, H., Bhojwani, D., Pauley, J.L., Pei, D., Cheng, C., Metzger, M.L., Howard, S.C., Rubnitz, J.E., Sandlund, J.T., Ribeiro, R.C., Leung, W., Campana, D., Pui, C.H. & Jeha, S. (2012) Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. British Journal of Haematology, 156, 275-279.
79. Iyengar, R., Handgretinger, R., Babarin-Dorner, A., Leimig, T., Otto, M., Geiger, T.L., Holladay, M.S., Houston, J. & Leung, W. (2003) Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy, 5, 479-484.
80. Jeha, S., Gandhi, V., Chan, K.W., McDonald, L., Ramirez, I., Madden, R., Rytting, M., Brandt, M., Keating, M., Plunkett, W. & Kantarjian, H. (2004) Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood, 103, 784-789.
81. Jeha, S., Razzouk, B., Rytting, M., Rheingold, S., Albano, E., Kadota, R., Luchtman-Jones, L., Bomgaars, L., Gaynon, P., Goldman, S., Ritchey, K., Arceci, R., Altman, A., Stine, K., Steinherz, L. & Steinherz, P. (2009) Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. Journal of Clinical Oncology, 27, 4392-4397.
82. Johnston, D.L., Alonzo, T.A., Gerbing, R.B., Lange, B.J. & Woods, W.G. (2005) Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. Journal of Clinical Oncology, 23, 9172-9178.
83. Kornblau, S.M., Womble, M., Qiu, Y.H., Jackson, C.E., Chen, W., Konopleva, M., Estey, E.H. & Andreeff, M. (2006) Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood, 108, 2358-2365.
84. Krance, R.A., Hurwitz, C.A., Head, D.R., Raimondi, S.C., Behm, F.G., Crews, K.R., Srivastava, D.K., Mahmoud, H., Roberts, W.M., Tong, X., Blakley, R.L. & Ribeiro, R.C. (2001) Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. Journal of Clinical Oncology, 19, 2804-2811.
85. Kuhn, M.W., Radtke, I., Bullinger, L., Goorha, S., Cheng, J., Edelmann, J., Gohlke, J., Su, X., Paschka, P., Pounds, S., Krauter, J., Ganser, A., Quessar, A., Ribeiro, R., Gaidzik, V.I., Shurtleff, S., Kronke, J., Holzmann, K., Ma, J., Schlenk, R.F., Rubnitz, J.E., Dohner, K., Dohner, H. & Downing, J.R. (2012) High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. Blood, 119, e67-e75.
86. Kurt, B., Flynn, P., Shenep, J.L., Pounds, S., Lensing, S., Ribeiro, R.C., Pui, C.H., Razzouk, B.I. & Rubnitz, J.E. (2008) Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer, 113, 376-382.
87. Lange, B.J., Smith, F.O., Feusner, J., Barnard, D.R., Dinndorf, P., Feig, S., Heerema, N.A., Arndt, C., Arceci, R.J., Seibel, N., Weiman, M., Dusenbery, K., Shannon, K., Luna-Fineman, S., Gerbing, R.B. & Alonzo, T.A. (2008) Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood, 111, 1044-1053.
88. Langebrake, C., Creutzig, U., Dworzak, M., Hrusak, O., Mejstrikova, E., Griesinger, F., Zimmermann, M. & Reinhardt, D. (2006) Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. Journal of Clinical Oncology, 24, 3686-3692.
89. Lehrnbecher, T., Zimmermann, M., Reinhardt, D., Dworzak, M., Stary, J. & Creutzig, U. (2007) Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood, 109, 936-943.
90. Leung, W. (2011) Use of NK cell activity in cure by transplant. British Journal of Haematology, 155, 14-29.
91. Leung, W., Iyengar, R., Triplett, B., Turner, V., Behm, F.G., Holladay, M.S., Houston, J. & Handgretinger, R. (2005) Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. Journal of Immunology, 174, 6540-6545.
92. Leung, W., Campana, D., Yang, J., Pei, D., Coustan-Smith, E., Gan, K., Rubnitz, J.E., Sandlund, J.T., Ribeiro, R.C., Srinivasan, A., Hartford, C., Triplett, B.M., Dallas, M., Pillai, A., Handgretinger, R., Laver, J.H. & Pui, C.H. (2011) High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood, 118, 223-230.
93. Leung, W., Pui, C.H., Coustan-Smith, E., Yang, J., Pei, D., Gan, K., Srinivasan, A., Hartford, C., Triplett, B.M., Dallas, M., Pillai, A., Shook, D., Rubnitz, J.E., Sandlund, J.T., Jeha, S., Inaba, H., Ribeiro, R.C., Handgretinger, R., Laver, J.H. & Campana, D. (2012) Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood, 120, 468-472.
94. Levis, M. (2011) FLT3/ITD AML and the law of unintended consequences. Blood, 117, 6987-6990.
95. Levis, M. & Small, D. (2003) FLT3: ITDoes matter in leukemia. Leukemia, 17, 1738-1752.
96. Levis, M., Ravandi, F., Wang, E.S., Baer, M.R., Perl, A., Coutre, S., Erba, H., Stuart, R.K., Baccarani, M., Cripe, L.D., Tallman, M.S., Meloni, G., Godley, L.A., Langston, A.A., Amadori, S., Lewis, I.D., Nagler, A., Stone, R., Yee, K., Advani, A., Douer, D., Wiktor-Jedrzejczak, W., Juliusson, G., Litzow, M.R., Petersdorf, S., Sanz, M., Kantarjian, H.M., Sato, T., Tremmel, L., Bensen-Kennedy, D.M., Small, D. & Smith, B.D. (2011) Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood, 117, 3294-3301.
97. Ley, T.J., Mardis, E.R., Ding, L., Fulton, B., McLellan, M.D., Chen, K., Dooling, D., Dunford-Shore, B.H., McGrath, S., Hickenbotham, M., Cook, L., Abbott, R., Larson, D.E., Koboldt, D.C., Pohl, C., Smith, S., Hawkins, A., Abbott, S., Locke, D., Hillier, L.W., Miner, T., Fulton, L., Magrini, V., Wylie, T., Glasscock, J., Conyers, J., Sander, N., Shi, X., Osborne, J.R., Minx, P., Gordon, D., Chinwalla, A., Zhao, Y., Ries, R.E., Payton, J.E., Westervelt, P., Tomasson, M.H., Watson, M., Baty, J., Ivanovich, J., Heath, S., Shannon, W.D., Nagarajan, R., Walter, M.J., Link, D.C., Graubert, T.A., DiPersio, J.F. & Wilson, R.K. (2008) DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature, 456, 66-72.
98. Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E., Kandoth, C., Payton, J.E., Baty, J., Welch, J., Harris, C.C., Lichti, C.F., Townsend, R.R., Fulton, R.S., Dooling, D.J., Koboldt, D.C., Schmidt, H., Zhang, Q., Osborne, J.R., Lin, L., O'Laughlin, M., McMichael, J.F., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Magrini, V.J., Vickery, T.L., Hundal, J., Cook, L.L., Conyers, J.J., Swift, G.W., Reed, J.P., Alldredge, P.A., Wylie, T., Walker, J., Kalicki, J., Watson, M.A., Heath, S., Shannon, W.D., Varghese, N., Nagarajan, R., Westervelt, P., Tomasson, M.H., Link, D.C., Graubert, T.A., DiPersio, J.F., Mardis, E.R. & Wilson, R.K. (2010) DNMT3A mutations in acute myeloid leukemia. New England Journal of Medicine, 363, 2424-2433.
99. Lie, S.O., Abrahamsson, J., Clausen, N., Forestier, E., Hasle, H., Hovi, L., Jonmundsson, G., Mellander, L. & Gustafsson, G. (2003) Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. British Journal of Haematology, 122, 217-225.
100. Lokken, A.A. & Zeleznik-Le, N.J. (2012) Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML. Cancer Cell, 21, 451-453.
101. Lowenberg, B., Ossenkoppele, G.J., van Putten, W., Schouten, H.C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., Biemond, B.J., Vellenga, E., van Marwijk, K.M., Verdonck, L.F., Beck, J., Dohner, H., Gratwohl, A., Pabst, T. & Verhoef, G. (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. New England Journal of Medicine, 361, 1235-1248.
102. Magee, J.A., Piskounova, E. & Morrison, S.J. (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell, 21, 283-296.
103. Majeti, R. (2011) Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene, 30, 1009-1019.
104. Majeti, R., Chao, M.P., Alizadeh, A.A., Pang, W.W., Jaiswal, S., Gibbs, Jr, K.D., van Rooijen, N. & Weissman, I.L. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell, 138, 286-299.
105. Marcucci, G., Haferlach, T. & Dohner, H. (2011) Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. Journal of Clinical Oncology, 29, 475-486.
106. Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., Koboldt, D.C., Fulton, R.S., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Locke, D.P., Magrini, V.J., Abbott, R.M., Vickery, T.L., Reed, J.S., Robinson, J.S., Wylie, T., Smith, S.M., Carmichael, L., Eldred, J.M., Harris, C.C., Walker, J., Peck, J.B., Du, F., Dukes, A.F., Sanderson, G.E., Brummett, A.M., Clark, E., McMichael, J.F., Meyer, R.J., Schindler, J.K., Pohl, C.S., Wallis, J.W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M.E., Ivy, J.V., Kalicki, J., Elliott, G., Ries, R.E., Payton, J.E., Westervelt, P., Tomasson, M.H., Watson, M.A., Baty, J., Heath, S., Shannon, W.D., Nagarajan, R., Link, D.C., Walter, M.J., Graubert, T.A., DiPersio, J.F., Wilson, R.K. & Ley, T.J. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. New England Journal of Medicine, 361, 1058-1066.
107. Mathews, V., George, B., Chendamarai, E., Lakshmi, K.M., Desire, S., Balasubramanian, P., Viswabandya, A., Thirugnanam, R., Abraham, A., Shaji, R.V., Srivastava, A. & Chandy, M. (2010) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. Journal of Clinical Oncology, 28, 3866-3871.
108. Meshinchi, S. & Appelbaum, F.R. (2009) Structural and functional alterations of FLT3 in acute myeloid leukemia. Clinical Cancer Research, 15, 4263-4269.
109. Meshinchi, S., Alonzo, T.A., Stirewalt, D.L., Zwaan, M., Zimmerman, M., Reinhardt, D., Kaspers, G.J., Heerema, N.A., Gerbing, R., Lange, B.J. & Radich, J.P. (2006a) Clinical implications of FLT3 mutations in pediatric AML. Blood, 108, 3654-3661.
110. Meshinchi, S., Arceci, R.J., Sanders, J.E., Smith, F.O., Woods, W.B., Radich, J.P. & Alonzo, T.A. (2006b) Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood, 108, 400-401.
111. Miller, J.S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S.A., Yun, G.H., Fautsch, S.K., McKenna, D., Le, C., DeFor, T.E., Burns, L.J., Orchard, P.J., Blazar, B.R., Wagner, J.E., Slungaard, A., Weisdorf, D.J., Okazaki, I.J. & McGlave, P.B. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 105, 3051-3057.
112. Molgaard-Hansen, L., Mottonen, M., Glosli, H., Jonmundsson, G.K., Abrahamsson, J. & Hasle, H. (2010) Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003. British Journal of Haematology, 151, 447-459.
113. Molgaard-Hansen, L., Glosli, H., Jahnukainen, K., Jarfelt, M., Jonmundsson, G.K., Malmros-Svennilson, J., Nysom, K. & Hasle, H. (2011) Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study. Pediatric Blood and Cancer, 57, 1222-1229.
114. Mulrooney, D.A., Dover, D.C., Li, S., Yasui, Y., Ness, K.K., Mertens, A.C., Neglia, J.P., Sklar, C.A., Robison, L.L. & Davies, S.M. (2008) Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study. Cancer, 112, 2071-2079.
115. von Neuhoff, C., Reinhardt, D., Sander, B., Zimmermann, M., Bradtke, J., Betts, D., Zemanova, Z., Stary, J., Bourquin, J.P., Haas, O., Dworzak, M. & Creutzig, U. (2010) Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. Journal of Clinical Oncology, 28, 2682-2689.
116. Nguyen, L.V., Vanner, R., Dirks, P. & Eaves, C.J. (2012) Cancer stem cells: an evolving concept. Nature Reviews Cancer, 12, 133-143.
117. Niewerth, D., Creutzig, U., Bierings, M.B. & Kaspers, G.J. (2010) A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood, 116, 2205-2214.
118. O'Brien, T.A., Russell, S.J., Vowels, M.R., Oswald, C.M., Tiedemann, K., Shaw, P.J., Lockwood, L., Teague, L., Rice, M. & Marshall, G.M. (2002) Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group. Blood, 100, 2708-2716.
119. Ohtake, S., Miyawaki, S., Fujita, H., Kiyoi, H., Shinagawa, K., Usui, N., Okumura, H., Miyamura, K., Nakaseko, C., Miyazaki, Y., Fujieda, A., Nagai, T., Yamane, T., Taniwaki, M., Takahashi, M., Yagasaki, F., Kimura, Y., Asou, N., Sakamaki, H., Handa, H., Honda, S., Ohnishi, K., Naoe, T. & Ohno, R. (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood, 117, 2358-2365.
120. Park, I.J., Park, J.E., Kim, H.J., Jung, H.J., Lee, W.G. & Cho, S.R. (2010) Acute myeloid leukemia with t(16;21)(q24;q22) and eosinophilia: case report and review of the literature. Cancer Genetics and Cytogenetics, 196, 105-108.
121. Patel, J.P., Gonen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., Huberman, K., Cheng, J., Viale, A., Socci, N.D., Heguy, A., Cherry, A., Vance, G., Higgins, R.R., Ketterling, R.P., Gallagher, R.E., Litzow, M., van den Brink, M.R., Lazarus, H.M., Rowe, J.M., Luger, S., Ferrando, A., Paietta, E., Tallman, M.S., Melnick, A., Abdel-Wahab, O. & Levine, R.L. (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. New England Journal of Medicine, 366, 1079-1089.
122. Perel, Y., Auvrignon, A., Leblanc, T., Vannier, J.P., Michel, G., Nelken, B., Gandemer, V., Schmitt, C., Lamagnere, J.P., de Lumley, L., Bader-Meunier, B., Couillaud, G., Schaison, G., Landman-Parker, J., Thuret, I., Dalle, J.H., Baruchel, A. & Leverger, G. (2002) Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucamie Aique Myeloide Enfant. Journal of Clinical Oncology, 20, 2774-2782.
123. Perel, Y., Auvrignon, A., Leblanc, T., Michel, G., Reguerre, Y., Vannier, J.P., Dalle, J.H., Gandemer, V., Schmitt, C., Mechinaud, F., Lejars, O., Piguet, C., Couillaud, G., Pautard, B., Landman-Parker, J., Thuret, I., Aladjidi, N., Baruchel, A. & Leverger, G. (2005) Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit-multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. Leukemia, 19, 2082-2089.
124. Pigazzi, M., Masetti, R., Martinolli, F., Manara, E., Beghin, A., Rondelli, R., Locatelli, F., Fagioli, F., Pession, A. & Basso, G. (2012) Presence of high-ERG expression is an independent unfavorable prognostic marker in MLL-rearranged childhood myeloid leukemia. Blood, 119, 1086-1087.
125. Pollard, J.A., Alonzo, T.A., Gerbing, R.B., Ho, P.A., Zeng, R., Ravindranath, Y., Dahl, G., Lacayo, N.J., Becton, D., Chang, M., Weinstein, H.J., Hirsch, B., Raimondi, S.C., Heerema, N.A., Woods, W.G., Lange, B.J., Hurwitz, C., Arceci, R.J., Radich, J.P., Bernstein, I.D., Heinrich, M.C. & Meshinchi, S. (2010) Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood, 115, 2372-2379.
126. Powell, B.L., Moser, B., Stock, W., Gallagher, R.E., Willman, C.L., Stone, R.M., Rowe, J.M., Coutre, S., Feusner, J.H., Gregory, J., Couban, S., Appelbaum, F.R., Tallman, M.S. & Larson, R.A. (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 116, 3751-3757.
127. Pui, C.H., Carroll, W.L., Meshinchi, S. & Arceci, R.J. (2011) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. Journal of Clinical Oncology, 29, 551-565.
128. Quintas-Cardama, A., Santos, F.P. & Garcia-Manero, G. (2011) Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia, 25, 226-235.
129. Radtke, I., Mullighan, C.G., Ishii, M., Su, X., Cheng, J., Ma, J., Ganti, R., Cai, Z., Goorha, S., Pounds, S.B., Cao, X., Obert, C., Armstrong, J., Zhang, J., Song, G., Ribeiro, R.C., Rubnitz, J.E., Raimondi, S.C., Shurtleff, S.A. & Downing, J.R. (2009) Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proceedings of the National Academy of Sciences of the USA, 106, 12944-12949.
130. Ravandi, F., Cortes, J.E., Jones, D., Faderl, S., Garcia-Manero, G., Konopleva, M.Y., O'Brien, S., Estrov, Z., Borthakur, G., Thomas, D., Pierce, S.R., Brandt, M., Byrd, A., Bekele, B.N., Pratz, K., Luthra, R., Levis, M., Andreeff, M. & Kantarjian, H.M. (2010) Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. Journal of Clinical Oncology, 28, 1856-1862.
131. Ravindranath, Y., Steuber, C.P., Krischer, J., Civin, C.I., Ducore, J., Vega, R., Pitel, P., Inoue, S., Bleher, E., Sexauer, C., Hutter, J. & Vietti, T. (1991) High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. Journal of Clinical Oncology, 9, 572-580.
132. Razzouk, B.I., Raimondi, S.C., Srivastava, D.K., Pritchard, M., Behm, F.G., Tong, X., Sandlund, J.T., Rubnitz, J.E., Pui, C.H. & Ribeiro, R.C. (2001) Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. Leukemia, 15, 1326-1330.
133. Reulen, R.C., Winter, D.L., Frobisher, C., Lancashire, E.R., Stiller, C.A., Jenney, M.E., Skinner, R., Stevens, M.C. & Hawkins, M.M. (2010) Long-term cause-specific mortality among survivors of childhood cancer. JAMA, 304, 172-179.
134. Rubnitz, J.E., Raimondi, S.C., Tong, X., Srivastava, D.K., Razzouk, B.I., Shurtleff, S.A., Downing, J.R., Pui, C.H., Ribeiro, R.C. & Behm, F.G. (2002) Favorable impact of the t(9;11) in childhood acute myeloid leukemia. Journal of Clinical Oncology, 20, 2302-2309.
135. Rubnitz, J.E., Razzouk, B.I., Lensing, S., Pounds, S., Pui, C.H. & Ribeiro, R.C. (2007) Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer, 109, 157-163.
136. Rubnitz, J.E., Crews, K.R., Pounds, S., Yang, S., Campana, D., Gandhi, V.V., Raimondi, S.C., Downing, J.R., Razzouk, B.I., Pui, C.H. & Ribeiro, R.C. (2009) Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia, 23, 1410-1416.
137. Rubnitz, J.E., Inaba, H., Dahl, G., Ribeiro, R.C., Bowman, W.P., Taub, J., Pounds, S., Razzouk, B.I., Lacayo, N.J., Cao, X., Meshinchi, S., Degar, B., Airewele, G., Raimondi, S.C., Onciu, M., Coustan-Smith, E., Downing, J.R., Leung, W., Pui, C.H. & Campana, D. (2010a) Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. The Lancet Oncology, 11, 543-552.
138. Rubnitz, J.E., Inaba, H., Ribeiro, R.C., Pounds, S., Rooney, B., Bell, T., Pui, C.H. & Leung, W. (2010b) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. Journal of Clinical Oncology, 28, 955-959.
139. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M.F. & Velardi, A. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 295, 2097-2100.
140. Ruggeri, L., Mancusi, A., Capanni, M., Urbani, E., Carotti, A., Aloisi, T., Stern, M., Pende, D., Perruccio, K., Burchielli, E., Topini, F., Bianchi, E., Aversa, F., Martelli, M.F. & Velardi, A. (2007) Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood, 110, 433-440.
141. Saber, W., Opie, S., Rizzo, J.D., Zhang, M.J., Horowitz, M.M. & Schriber, J. (2012) Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood, 119, 3908-3916.
142. Sander, A., Zimmermann, M., Dworzak, M., Fleischhack, G., von Neuhoff, C., Reinhardt, D., Kaspers, G.J. & Creutzig, U. (2010) Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia, 24, 1422-1428.
143. Sanz, M.A. & Lo-Coco, F. (2011) Modern approaches to treating acute promyelocytic leukemia. Journal of Clinical Oncology, 29, 495-503.
144. Sato, T., Yang, X., Knapper, S., White, P., Smith, B.D., Galkin, S., Small, D., Burnett, A. & Levis, M. (2011) FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood, 117, 3286-3293.
145. Shaw, P.J., Kan, F., Woo, A.K., Spellman, S.R., Aljurf, M., Ayas, M., Burke, M., Cairo, M.S., Chen, A.R., Davies, S.M., Frangoul, H., Gajewski, J., Gale, R.P., Godder, K., Hale, G.A., Heemskerk, M.B., Horan, J., Kamani, N., Kasow, K.A., Chan, K.W., Lee, S.J., Leung, W.H., Lewis, V.A., Miklos, D., Oudshoorn, M., Petersdorf, E.W., Ringden, O., Sanders, J., Schultz, K.R., Seber, A., Setterholm, M., Wall, D.A., Yu, L. & Pulsipher, M.A. (2010) Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood, 116, 4007-4015.
146. Shenoy, S. & Smith, F.O. (2008) Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin. Bone Marrow Transplantation, 41, 141-148.
147. Sievers, E.L., Lange, B.J., Buckley, J.D., Smith, F.O., Wells, D.A., Daigneault-Creech, C.A., Shults, K.E., Bernstein, I.D. & Loken, M.R. (1996) Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. Journal of the National Cancer Institute, 88, 1483-1488.
148. Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Lowenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., van Dongen, J.J., Bernstein, I.D. & Appelbaum, F.R. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33- positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19, 3244-3254.
149. Sievers, E.L., Lange, B.J., Alonzo, T.A., Gerbing, R.B., Bernstein, I.D., Smith, F.O., Arceci, R.J., Woods, W.G. & Loken, M.R. (2003) Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood, 101, 3398-3406.
150. Slovak, M.L., Gundacker, H., Bloomfield, C.D., Dewald, G., Appelbaum, F.R., Larson, R.A., Tallman, M.S., Bennett, J.M., Stirewalt, D.L., Meshinchi, S., Willman, C.L., Ravindranath, Y., Alonzo, T.A., Carroll, A.J., Raimondi, S.C. & Heerema, N.A. (2006) A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia, 20, 1295-1297.
151. Smith, C.C., Wang, Q., Chin, C.S., Salerno, S., Damon, L.E., Levis, M.J., Perl, A.E., Travers, K.J., Wang, S., Hunt, J.P., Zarrinkar, P.P., Schadt, E.E., Kasarskis, A., Kuriyan, J. & Shah, N.P. (2012) Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature, 485, 260-263.
152. Staffas, A., Kanduri, M., Hovland, R., Rosenquist, R., Ommen, H.B., Abrahamsson, J., Forestier, E., Jahnukainen, K., Jonsson, O.G., Zeller, B., Palle, J., Lonnerholm, G., Hasle, H., Palmqvist, L. & Ehrencrona, H. (2011) Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood, 118, 5905-5913.
153. Stevens, R.F., Hann, I.M., Wheatley, K. & Gray, R.G. (1998) Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. British Journal of Haematology, 101, 130-140.
154. Sung, L., Lange, B.J., Gerbing, R.B., Alonzo, T.A. & Feusner, J. (2007) Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood, 110, 3532-3539.
155. Taga, T., Shimomura, Y., Horikoshi, Y., Ogawa, A., Itoh, M., Okada, M., Ueyama, J., Higa, T., Watanabe, A., Kanegane, H., Iwai, A., Saiwakawa, Y., Kogawa, K., Yamanaka, J. & Tsurusawa, M. (2011) Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study. Pediatric Blood and Cancer, 57, 36-40.
156. Tallman, M.S. & Altman, J.K. (2009) How I treat acute promyelocytic leukemia. Blood, 114, 5126-5135.
157. Testi, A.M., Biondi, A., Lo, C.F., Moleti, M.L., Giona, F., Vignetti, M., Menna, G., Locatelli, F., Pession, A., Barisone, E., De Rossi, G., Diverio, D., Micalizzi, C., Arico, M., Basso, G., Foa, R. & Mandelli, F. (2005) GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood, 106, 447-453.
158. Tomizawa, D., Tabuchi, K., Kinoshita, A., Hanada, R., Kigasawa, H., Tsukimoto, I. & Tsuchida, M. (2007) Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. Pediatric Blood and Cancer, 49, 127-132.
159. Tsukimoto, I., Tawa, A., Horibe, K., Tabuchi, K., Kigasawa, H., Tsuchida, M., Yabe, H., Nakayama, H., Kudo, K., Kobayashi, R., Hamamoto, K., Imaizumi, M., Morimoto, A., Tsuchiya, S. & Hanada, R. (2009) Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. Journal of Clinical Oncology, 27, 4007-4013.
160. Tukenova, M., Guibout, C., Oberlin, O., Doyon, F., Mousannif, A., Haddy, N., Guerin, S., Pacquement, H., Aouba, A., Hawkins, M., Winter, D., Bourhis, J., Lefkopoulos, D., Diallo, I. & de Vathaire, F. (2010) Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. Journal of Clinical Oncology, 28, 1308-1315.
161. Uy, G.L., Rettig, M.P., Motabi, I.H., McFarland, K., Trinkaus, K.M., Hladnik, L.M., Kulkarni, S., Abboud, C.N., Cashen, A.F., Stockerl-Goldstein, K.E., Vij, R., Westervelt, P. & DiPersio, J.F. (2012) A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood, 119, 3917-3924.
162. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.
163. van der Velden, V.H.J., van der Sluijs-Geling, A., Gibson, B.E.S., te Marvelde, J.G., Hoogeveen, P.G., Hop, W.C.J., Wheatley, K., Bierings, M.B., Schuurhuis, G.J., de Graaf, S.S.N., van Wering, E.R. & van Dongen, J.J.M. (2010) Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia, 24, 1599-1606.
164. Walter, M.J., Shen, D., Ding, L., Shao, J., Koboldt, D.C., Chen, K., Larson, D.E., McLellan, M.D., Dooling, D., Abbott, R., Fulton, R., Magrini, V., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Fan, X., Grillot, M., Witowski, S., Heath, S., Frater, J.L., Eades, W., Tomasson, M., Westervelt, P., DiPersio, J.F., Link, D.C., Mardis, E.R., Ley, T.J., Wilson, R.K. & Graubert, T.A. (2012) Clonal architecture of secondary acute myeloid leukemia. New England Journal of Medicine, 366, 1090-1098.
165. Wells, R.J., Woods, W.G., Lampkin, B.C., Nesbit, M.E., Lee, J.W., Buckley, J.D., Versteeg, C. & Hammond, G.D. (1993) Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. Journal of Clinical Oncology, 11, 538-545.
166. Wells, R.J., Woods, W.G., Buckley, J.D., Odom, L.F., Benjamin, D., Bernstein, I., Betcher, D., Feig, S., Kim, T., Ruymann, F., Smithson, W., Srivastava, A., Tannous, R., Buckley, C.M., Whitt, J.K., Wolff, L. & Lampkin, B.C. (1994) Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study. Journal of Clinical Oncology, 12, 2367-2377.
167. Wells, R.J., Adams, M.T., Alonzo, T.A., Arceci, R.J., Buckley, J., Buxton, A.B., Dusenbery, K., Gamis, A., Masterson, M., Vik, T., Warkentin, P. & Whitlock, J.A. (2003) Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. Journal of Clinical Oncology, 21, 2940-2947.
168. Woods, W.G., Neudorf, S., Gold, S., Sanders, J., Buckley, J.D., Barnard, D.R., Dusenbery, K., DeSwarte, J., Arthur, D.C., Lange, B.J. & Kobrinsky, N.L. (2001) A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood, 97, 56-62.
169. Yates, J., Glidewell, O., Wiernik, P., Cooper, M.R., Steinberg, D., Dosik, H., Levy, R., Hoagland, C., Henry, P., Gottlieb, A., Cornell, C., Berenberg, J., Hutchison, J.L., Raich, P., Nissen, N., Ellison, R.R., Frelick, R., James, G.W., Falkson, G., Silver, R.T., Haurani, F., Green, M., Henderson, E., Leone, L. & Holland, J.F. (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood, 60, 454-462.
170. Zarrinkar, P.P., Gunawardane, R.N., Cramer, M.D., Gardner, M.F., Brigham, D., Belli, B., Karaman, M.W., Pratz, K.W., Pallares, G., Chao, Q., Sprankle, K.G., Patel, H.K., Levis, M., Armstrong, R.C., James, J. & Bhagwat, S.S. (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 114, 2984-2992.
171. Zeng, Z., Shi, Y.X., Samudio, I.J., Wang, R.Y., Ling, X., Frolova, O., Levis, M., Rubin, J.B., Negrin, R.R., Estey, E.H., Konoplev, S., Andreeff, M. & Konopleva, M. (2009) Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood, 113, 6215-6224.
172. Zhang, W., Konopleva, M., Shi, Y.X., McQueen, T., Harris, D., Ling, X., Estrov, Z., Quintas-Cardama, A., Small, D., Cortes, J. & Andreeff, M. (2008) Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Journal of the National Cancer Institute, 100, 184-198.
173. Zhou, J., Zhang, Y., Li, J., Li, X., Hou, J., Zhao, Y., Liu, X., Han, X., Hu, L., Wang, S., Zhao, Y., Zhang, Y., Fan, S., Lv, C., Li, L. & Zhu, L. (2010) Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood, 115, 1697-1702.
174. Zwaan, C.M., Reinhardt, D., Zimmerman, M., Hasle, H., Stary, J., Stark, B., Dworzak, M., Creutzig, U. & Kaspers, G.J. (2010) Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. British Journal of Haematology, 148, 768-776.